GGrantIndex
Sort

48,018 grants matching immunotherapy

Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer

$370,575
Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA

Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer

$370,575
Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01

$370,575
Melody A Swartz · University Of Chicago · R01 · FY2021 · CA

TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer

$370,575
Rafet Basar · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors

$370,575
Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA

Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy

$370,575
Wei Gu · Columbia University Health Sciences · R01 · FY2025 · CA

Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis

$370,575
Florencia McAllister · University Of Tx Md Anderson Can Ctr · R37 · FY2021 · CA

Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors

$370,575
Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

CLL clonal evolution and the development of therapy-driven resistance

$370,572
Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · P01 · FY2017 · CA

Mechanism of self antigen-induced non-responsivesness in CD8 T cells

$370,564
Matthew F Mescher · University Of Minnesota · P01 · FY2015 · AI

Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages

$370,554
James Louis Rubenstein · University Of California, San Francisco · R01 · FY2016 · CA

Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages

$370,554
James Louis Rubenstein · University Of California, San Francisco · R01 · FY2017 · CA

Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages

$370,554
James Louis Rubenstein · University Of California, San Francisco · R01 · FY2015 · CA

Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance

$370,552
Fernando Macian · Albert Einstein College Of Medicine · R01 · FY2019 · CA

Project 1: Immune Memory

$370,523
Rafi Ahmed · Emory University · U19 · FY2022 · AI

T Cell Reagent Research for Monitoring T Cell in Food Allergy

$370,520
Kari C. Nadeau · Stanford University · U01 · FY2018 · AI

Mechanistic investigations of microbiome-driven aryl hydrocarbon receptor activity and macrophage function in pancreatic cancer.

$370,513
Tracy L McGaha · University Health Network · R01 · FY2025 · CA

Autoimmune vitiligo and tolerance in the immune response to a melanoma antigen

$370,513
Victor H. Engelhard · University Of Virginia · R01 · FY2008 · AI

Skeletal survivorship and immune therapy: The effects of nivolumab on bone metabolism in renal cell carcinoma

$370,511
Kendall Moseley · Johns Hopkins University · R21 · FY2019 · AR

Innate Immune Therapy for B-Cell Malignancies

$370,509
John C Byrd · Ohio State University · P01 · FY2014 · CA

HSP 110 and its role in cancer therapy

$370,504
John R. Subjeck · Roswell Park Cancer Institute Corp · R01 · FY2011 · CA

Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma

$370,500
Roger S Lo · University Of California Los Angeles · R01 · FY2020 · CA

Develop a Therapeutic Nano-vaccine against Head and Neck Cancer

$370,500
Yu Leo Lei · University Of Michigan At Ann Arbor · R01 · FY2019 · DE

Develop a Therapeutic Nano-vaccine against Head and Neck Cancer

$370,500
Yu Leo Lei · University Of Michigan At Ann Arbor · R01 · FY2021 · DE

FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma

$370,500
Andrew E Aplin · Thomas Jefferson University · R01 · FY2020 · CA